Please login to the form below

Not currently logged in
Email:
Password:

GSK collaborates with SuperGen

GSK has entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets with SuperGen

GlaxoSmithKline (GSK) has entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets with SuperGen, a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signalling modulation. 

Under the terms of the agreement, SuperGen will progress candidate compounds through to early clinical proof of concept, after which GSK will have the right to exercise an option to develop further and commercialise resulting production on a global basis.

SuperGen will receive $5m upfront, inclusive of a $3m common stock investment, priced at a premium to market. Total potential development and commercialisation milestones payable to SuperGen could exceed $375m. This is in addition to the potential for tiered royalties payable on net sales of any products.
 

26th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics